美国 · SEC FORM 4
Protagonist Therapeutics, Inc
PTGX · Nasdaq · CIK 0001377121 · Healthcare · Biotechnology
内部人信号
0 qualifying P purchase groups
当前 180 天评分窗口
35 同一窗口内观察到的 Form 4 交易行
16 sales · 19 期权、代扣税、授予、赠与或其他交易行
为什么没有活跃信号？
评分构成
活跃窗口内没有合资格买入，因此不计算分数。缺失的输入不会被当作零分或看空信号。
为什么没有分数？
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示，不会形成负分。
卖出和其他 Form 4 活动会单独显示，不会形成负面买入信号。没有买入不会被评分为看空。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型；卖出仅作为背景。
—
买方广度、集中度与聚集买入
合资格买入进入 180 天研究窗口后，这些模块才会启用。
信号历史
Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2020-03-12 · SELICK HAROLD E.
近期 Form 4 活动
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
该股票尚未获取市场背景。每日任务会轮转处理美国股票池。
空头余额
空头余额是券商向 FINRA 申报的外部背景数据，不影响内部人信号。
- 空头股数
- 9,345,382
- 上期报告
- 8,140,194
- 日均成交量
- 813,300
- 回补天数
- 11.5
FINRA 结算日：2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2020-03-12 | SELICK HAROLD E | 买入 (P) | Common Stock | 12,000 | USD 6.70 | USD 80,400 | SEC 申报 ↗ |
Form 4 申报证据
84 transaction lines in the latest 365-day window; 239 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-09-30 | Ali Asif | 卖出 (S) | Common Stock | 58,629 | USD 141.78 | USD 8,312,294 | SEC 申报 ↗ |
| 2026-09-30 | Ali Asif | 期权行权／转换 (M) | Common Stock | 58,629 | USD 23.72 | USD 1,390,735 | SEC 申报 ↗ |
| 2026-09-10 | PATEL DINESH V PH D | 卖出 (S) | Common Stock | 7,278 | USD 144.10 | USD 1,048,760 | SEC 申报 ↗ |
展开近期 Form 4 证据 (30 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-09-30 | Ali Asif | 卖出 (S) | Common Stock | 58,629 | USD 141.78 | USD 8,312,294 | SEC 申报 ↗ |
| 2026-09-30 | Ali Asif | 期权行权／转换 (M) | Common Stock | 58,629 | USD 23.72 | USD 1,390,735 | SEC 申报 ↗ |
| 2026-09-10 | PATEL DINESH V PH D | 卖出 (S) | Common Stock | 7,278 | USD 144.10 | USD 1,048,760 | SEC 申报 ↗ |
| 2026-09-10 | PATEL DINESH V PH D | 期权行权／转换 (M) | Common Stock | 7,278 | USD 21.58 | USD 157,059 | SEC 申报 ↗ |
| 2026-09-09 | PATEL DINESH V PH D | 卖出 (S) | Common Stock | 63,548 | USD 146.18 | USD 9,289,447 | SEC 申报 ↗ |
| 2026-09-09 | PATEL DINESH V PH D | 期权行权／转换 (M) | Common Stock | 63,548 | USD 21.58 | USD 1,371,366 | SEC 申报 ↗ |
| 2026-09-08 | PATEL DINESH V PH D | 卖出 (S) | Common Stock | 54,174 | USD 145.87 | USD 7,902,361 | SEC 申报 ↗ |
| 2026-09-08 | PATEL DINESH V PH D | 期权行权／转换 (M) | Common Stock | 54,174 | USD 21.58 | USD 1,169,075 | SEC 申报 ↗ |
| 2026-09-03 | PATEL DINESH V PH D | 赠与 (G) | Common Stock | 510 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-08-11 | PATEL DINESH V PH D | 卖出 (S) | Common Stock | 34,239 | USD 148.52 | USD 5,085,176 | SEC 申报 ↗ |
| 2026-08-11 | PATEL DINESH V PH D | 期权行权／转换 (M) | Common Stock | 34,239 | USD 21.58 | USD 738,878 | SEC 申报 ↗ |
| 2026-08-10 | PATEL DINESH V PH D | 卖出 (S) | Common Stock | 65,761 | USD 149.11 | USD 9,805,623 | SEC 申报 ↗ |
| 2026-08-10 | PATEL DINESH V PH D | 期权行权／转换 (M) | Common Stock | 65,761 | USD 21.58 | USD 1,419,122 | SEC 申报 ↗ |
| 2026-06-23 | Waddill William D. | 卖出 (S) | Common Stock | 9,000 | USD 117.94 | USD 1,061,460 | SEC 申报 ↗ |
| 2026-06-23 | Waddill William D. | 期权行权／转换 (M) | Common Stock | 9,000 | USD 16.54 | USD 148,860 | SEC 申报 ↗ |
| 2026-06-10 | Waddill William D. | 卖出 (S) | Common Stock | 9,000 | USD 107.68 | USD 969,120 | SEC 申报 ↗ |
| 2026-06-10 | Waddill William D. | 期权行权／转换 (M) | Common Stock | 9,000 | USD 14.96 | USD 134,640 | SEC 申报 ↗ |
| 2026-05-29 | Waddill William D. | 卖出 (S) | Common Stock | 9,000 | USD 99.64 | USD 896,760 | SEC 申报 ↗ |
| 2026-05-29 | Waddill William D. | 期权行权／转换 (M) | Common Stock | 9,000 | USD 11.80 | USD 106,200 | SEC 申报 ↗ |
| 2026-05-12 | PATEL DINESH V PH D | 卖出 (S) | Common Stock | 75,000 | USD 100.12 | USD 7,509,000 | SEC 申报 ↗ |
| 2026-05-12 | PATEL DINESH V PH D | 期权行权／转换 (M) | Common Stock | 75,000 | USD 21.58 | USD 1,618,500 | SEC 申报 ↗ |
| 2026-05-12 | PATEL DINESH V PH D | 卖出 (S) | Common Stock | 75,000 | USD 100.12 | USD 7,509,000 | SEC 申报 ↗ |
| 2026-05-12 | PATEL DINESH V PH D | 期权行权／转换 (M) | Common Stock | 75,000 | USD 21.58 | USD 1,618,500 | SEC 申报 ↗ |
| 2026-05-08 | Giraudo Bryan | 卖出 (S) | Common Stock | 11,130 | USD 100.00 | USD 1,113,000 | SEC 申报 ↗ |
| 2026-05-07 | Giraudo Bryan | 卖出 (S) | Common Stock | 48,000 | USD 100.12 | USD 4,805,880 | SEC 申报 ↗ |
| 2026-05-07 | Giraudo Bryan | 期权行权／转换 (M) | Common Stock | 36,000 | USD 6.63 | USD 238,560 | SEC 申报 ↗ |
| 2026-04-23 | PATEL DINESH V PH D | 赠与 (G) | Common Stock | 1,460 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-04-20 | Ali Asif | 卖出 (S) | Common Stock | 1,750 | USD 105.47 | USD 184,572 | SEC 申报 ↗ |
| 2026-03-26 | SELICK HAROLD E | 卖出 (S) | Common Stock | 24,000 | USD 105.00 | USD 2,520,000 | SEC 申报 ↗ |
| 2026-03-26 | SELICK HAROLD E | 期权行权／转换 (M) | Common Stock | 24,000 | USD 12.88 | USD 309,120 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-18 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | PTGX |
| CIK | 0001377121 |
| 行业 | Healthcare |
| 细分行业 | Biotechnology Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 239 transaction lines from 2020-03-12 to 2026-09-30 1 P purchase lines · 88 S sale lines · 150 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.